Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

daclizumab

Biogen Idec building

Biogen’s Aduhelm unlikely to get approval in Europe

In another setback for the controversial Alzheimer’s disease antibody, the EMA’s review committee has voted against recommending the treatment

- PMLiVE

Eisai/Biogen present more data on antibody for Alzheimer’s disease

Phase 2 data shows lecanemab offers a consistent ‘robust’ effect against Alzheimer’s disease, while the phase 3 programme will test plasma biomarkers to identify preclinical disease

Biogen Idec building

Biogen investigating death linked to Aduhelm

The death of a 75-year-old patient taking Biogen’s Aduhelm has raised yet more questions around the recently approved Alzheimer’s therapy

Biogen Idec building

Biogen’s ALS drug tofersen misses phase 3 endpoint

Following these results, Biogen will now expand its early access programme for tofersen to enable all eligible SOD1-ALS patients worldwide to receive the drug free of charge

Biogen Idec building

Data shows patients treated with Biogen’s MS therapies mount an effective antibody response to COVID-19 vaccination

New MS PATHS data was presented at ECTRIMS 2021

Biogen Idec building

Rolling submission granted for Biogen/Eisai’s next Alzheimer’s antibody

The FDA will review the data for Biogen and Eisai’s anti-amyloid beta protofibril antibody, lecanemab, on an ongoing basis

Biogen Idec building

Rocky start for Biogen’s Alzheimer’s drug Aduhelm

Controversial Alzheimer’s treatment Aduhelm is struggling to realise its potential, with only 100 patients receiving the therapy so far in the US

Biogen Idec building

Biogen’s Vumerity recommended by CHMP in MS

A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis

Biogen Idec building

Embattled Biogen talks up Aduhelm

Biogen CEO admitted the company was experiencing “near-term challenges” after the controversial approval of Alzheimer’s drug, Aduhelm

- PMLiVE

Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm

Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its dealings with the company.

- PMLiVE

Mixed results for AC Immune’s promising Alzheimer’s antibody

Shares in AC Immune rose more than 75% on the news that semorinemab met one of two study endpoints

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links